Penny Gilbert from Powell Gilbert LLP explains the position of biosimilars in the pharmaceutical industry. Biosimilars are essentially generic versions of biologics. Traditional generic compounds are…
Adam Mossoff (Professor of Law, George Mason University) states that much of the focus in the USA is around litigation, but patents are not simply tools for litigation, they are commercial assets.…
Justin Watts (Freshfields) asked whether the strict test for priority fails to appreciate the early stage at which the inventor will be enunciating the invention (often in multiple jurisdictions). He…
Marleen H J van den Hors (BarentsKrans in the Netherlands) dealt with the interesting question of enforcement of second medical use patents and suggested that regulatory changes might be required to…
There has been an explosion of anti-trust cases at the EC, which is of concern to the Deputy Director for Antitrust (European Commission) Cecilio Madero Villarejo. Some of these cases involve non-EU…
A panel of international judges gave their interesting perspectives on the tribunals on which they serve and the cases which they hear.
Annabelle Bennett (Federal Court of Australia) discussing case…
Dimitrios T Drivas (White & Case) gave the speedy run down on the following points and cases, which some might find useful for following up on points of interest:
Supreme Court
The decision that…
The Hon. Ryuichi Shitara (Chief Judge, Intellectual Property High Court, Tokyo, Japan) gives an insight into the practice in Japan of Court-encouraged settlement. He explains that it is not…
The Unitary Patent and the UPC in Practice
Paul England (Taylor Wessing) described the infringement position under the UPC Agreement and the UP Regulation (1257/2012). He explained that there was…
A View from the Task Force and the Judiciary
The topic of injunctions under the UPCA was raised by Johannes Karcher (Head of the Task Force, EU Patent and Unified Patent Court, Germany) with…
